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Abstract
Background: For around a third of people with a diagnosis of schizophrenia, the condition proves to respond
poorly to treatment with many typical and atypical antipsychotics. This is commonly referred to as treatment-resistant
schizophrenia. Clozapine is the only antipsychotic with convincing efficacy for people whose symptoms are considered
treatment-resistant to antipsychotic medication. However, 30–40 % of such conditions will have an insufficient
response to the drug. Cognitive behavioural therapy has been shown to be an effective treatment for schizophrenia
when delivered in combination with antipsychotic medication, with several meta-analyses showing robust support
for this approach. However, the evidence for the effectiveness of cognitive behavioural therapy for people with a
schizophrenia diagnosis whose symptoms are treatment-resistant to antipsychotic medication is limited. There is
a clinical and economic need to evaluate treatments to improve outcomes for people with such conditions.
Methods/design: A parallel group, prospective randomised, open, blinded evaluation of outcomes design will be
used to compare a standardised cognitive behavioural therapy intervention added to treatment as usual versus
treatment as usual alone (the comparator group) for individuals with a diagnosis of schizophrenia for whom an
adequate trial of clozapine has either not been possible due to tolerability problems or was not associated with a
sufficient therapeutic response. The trial will be conducted across five sites in the United Kingdom.
Discussion: The recruitment target of 485 was achieved, with a final recruitment total of 487. This trial is the largest
definitive, pragmatic clinical and cost-effectiveness trial of cognitive behavioural therapy for people with schizophrenia
whose symptoms have failed to show an adequate response to clozapine treatment. Using a prognostic risk model,
baseline information will be used to explore whether there are identifiable subgroups for which the treatment
effect is greatest.
Trial registration: Current Controlled Trials ISRCTN99672552. Registered 29th November 2012.
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Background
In around a third of people with a diagnosis of schizo-
phrenia, symptoms will respond poorly to standard
treatment with antipsychotic medication. In a relatively
small proportion of people, schizophrenia proves to be
treatment-resistant in its early stages, failing to remit
after the first exposure to antipsychotic medication [1].
However, more commonly treatment-resistance emerges
over time: the symptoms become progressively less res-
ponsive to medication with subsequent relapses [2].
The clinical and economic costs of providing treat-
ment for people who have a diagnosis of schizophrenia
and whose symptoms have shown a poor response to
treatment with antipsychotic medication is a major chal-
lenge in everyday psychiatry. It is estimated that the total
societal cost of schizophrenia in the UK is £11.8 billion
per year with the cost to the public sector estimated at
£7.2 billion [3].
For people meeting diagnostic criteria for treatment-
resistant schizophrenia, the economic costs are greater
as longer-term residential and intensive community
treatments are usually required [4, 5]. Even for a first
episode of psychosis, symptoms may not remit in around
10 % over the first 12 months following initiation of
treatment. There is clinical and economic need to evalu-
ate treatments to improve outcomes for people who
meet criteria for a diagnosis of schizophrenia with
treatment-resistant symptoms.
Clozapine is the only antipsychotic with convincing evi-
dence of efficacy for strictly-defined, treatment-resistant
schizophrenia [2]. Meta-analyses have demonstrated that
clozapine is superior to typical antipsychotics in im-
proving positive and negative symptoms of schizophre-
nia [6]. However, clozapine has limited efficacy for such
conditions, with 30–40 % showing an inadequate res-
ponse to the drug [6]. In some people, a range of poten-
tially serious side effects from clozapine, such as seizures,
sedation and tachycardia, may prevent the optimal dose
being reached. In the short term, metabolic side effects
add to the known cardiometabolic risk factors in people
diagnosed with a psychotic disorder and further increase
the likelihood of developing diabetes and cardiovascular
disease. The long-term adverse effects of antipsychotics
are becoming increasingly recognised as problematic [7],
so a demonstration of the benefits of alternative treatment
options for this group of people is required. In recent
years, the cognitive approach, successful in helping de-
pression and anxiety, [8] has been applied to our under-
standing and treatment of psychosis. The basis of the
cognitive approach is that the way that we interpret events
will have consequences for how we feel and behave, and
that such interpretations are often maintained by unhelp-
ful thinking biases and behavioural responses. There have
been several cognitive models of psychosis and psychotic
experiences outlined [9–15], which suggest that it is how
people interpret psychotic phenomena that accounts
for distress and disability, rather than the psychotic ex-
periences themselves. There are several comprehensive
treatment manuals that describe the application of such
models in greater detail [12–15]. Cognitive behavioural
therapy for psychosis (CBTp) is effective and safe when
delivered in combination with antipsychotic medication,
with several meta-analyses showing robust support for
this approach [16–20]. Recent meta-analyses have shown
CBTp is more effective than other psychological therapies
in reducing positive symptoms of psychosis, such as hallu-
cinations and delusional beliefs [21].
To date, six randomised controlled trials (RCT) of
CBT for people with a diagnosis of schizophrenia whose
symptoms are treatment resistant to antipsychotic medi-
cation have been conducted [22–27] with a total sample
of 361 participants. Of these, five trials targeted a partici-
pant population that met criteria similar to those for the
initiation of clozapine treatment and only one small study
has examined the efficacy of CBT for strictly defined
clozapine-resistant psychosis [22]. Analysis of effect sizes
on positive symptoms from the six existing trials that
have focused on a treatment-resistant and/or clozapine-
resistant population shows a mean effect size of 0.53.
This is similar to the overall effect size of 0.4 from
Wykes et al’s review of CBTp [17]. However, these effect
sizes may be inflated as all studies were small and there-
fore the aggregate effect size may be biased upwards as
a result of publication bias and poor quality of the
methodology.
There are few studies from which to estimate the likely
effect sizes of CBTp for people with a schizophrenia
diagnosis who are unable to tolerate clozapine. How-
ever, results of a feasibility RCT of CBTp for people
with schizophrenia spectrum disorders not taking anti-
psychotic medication found that CBTp significantly
reduced psychiatric symptoms in comparison to treat-
ment as usual and demonstrated it was both safe and
acceptable [28].
CBTp has the potential to help alleviate symptoms
and improve quality of life in people meeting criteria
for treatment-resistant schizophrenia and there are
suggestions that it can help those who are not taking
antipsychotics. However, there is insufficient research
regarding CBTp for people with an inadequate response
to clozapine or who are unable to tolerate the drug.
The FOCUS trial aims to address the question of whether,
Cognitive Behavioural Therapy (CBT) is clinically and cost
effective and an acceptable treatment for people with
confirmed treatment-resistant schizophrenia that is poorly
responsive to an adequate trial of clozapine monotherapy
(or unable to tolerate such a trial)? We will test the
hypotheses that:
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1. In people with a diagnosis of schizophrenia
spectrum disorder who have an inadequate
response to or are unable to tolerate clozapine,
CBTp plus Treatment As Usual (TAU) will lead
to improvement in psychotic symptoms, measured
using a psychiatric interview (PANSS), over a
21-month follow-up period compared with
TAU alone.
2. CBTp plus TAU will lead to improved quality of life
and user-defined recovery compared to TAU alone.
3. CBTp plus TAU will lead to a reduction in affective
symptoms and negative symptoms compared to
TAU alone.
4. CBTp plus TAU will be cost effective compared to
TAU alone.
In addition, we will develop a prognostic risk model
that identifies baseline factors that predict good response
to CBTp.
Methods and design
FOCUS is a parallel group, prospective, randomised,
open, blinded evaluation (PROBE) of outcomes design
comparing a standardised cognitive behavioural therapy
for psychosis (CBTp) intervention added to treatment as
usual (TAU) versus TAU alone (the comparator group) in
individuals who are unable to tolerate clozapine or whose
symptoms have failed to respond adequately to the drug.
The trial has five sites across the United Kingdom
(UK; Edinburgh, Glasgow, Manchester, Newcastle and
Southampton). Our trial is designed as definitive, prag-
matic, clinical and cost effectiveness trial. The study is
funded by the National Institute for Health Research
(NIHR) Heath Technology Assessment (HTA) program.
The funders commissioned a call to answer the research
question: what is the effectiveness and cost effectiveness
of cognitive behaviour therapy for individuals who have
treatment-resistant schizophrenia? The funder specified
that important outcomes should be change in psychiatric
symptoms and that other outcomes should be change in
psychological measures, measures of function, frequency
of relapse, health service use, quality of life, cost effective-
ness. In addition, it was specified that the minimum
follow-up should be 12 months and that the comparator
should be treatment as usual. Recruitment of participants
commenced on 1st January 2013 and ended on 31st May
2015. The trial is currently ongoing and data collection
will continue until March 2017.
It would have been unethical to restrict the therapeutic
options of the clinical teams participating; therefore, we
did not ask referrers to withhold any treatment from the
‘treatment as usual’ options. Our approach is, accordingly,
to record the use of all other medication and psychological
therapies, document details of dosage, and ensure the
follow-up of all randomised participants, irrespective of
the interventions that they subsequently received.
Randomisation was in the ratio 1:1 to the two groups
and was stratified by centre. Randomisation (at the in-
dividual level) was independent and concealed, using
randomised-permuted blocks of random size, which
was administered via a study-specific web-based portal
(OpenCDMS, a web-based system developed with the
National Institute for Mental Health (NIHR) Clinical
Research Network (CRN) - Mental Health). The alloca-
tion was made known to the trial manager (in order to
monitor adherence to the randomisation algorithm),
the trial administrator and trial therapists by email. The
allocation was also made known to the participant by
letter from the trial administrator. The research assis-
tants (RA) are blinded to the allocation code in order
to protect against bias. Blindness is maintained using a
wide range of measures, such as separate offices for the
therapists and research assistants (RA), protocols for
answering telephones, message taking and secretarial
support, separate diaries, pigeon holes and data-file se-
curity. The Independent Data Monitoring Committee
(IDMC) and Trial Steering Committee (TSC) monitor
un-blinding by each centre to implement corrective
action if necessary. If a blind break occurs, where pos-
sible, a new RA who is blind to allocation is identified
for subsequent follow-up assessments.
The trial has been approved by the National Research
Ethics Committee (NRES Committee Northwest-Lancaster)
(12/NW/0520). Ethical approval was granted on 13th
August 2012. The current version of ethics approved proto-
col is version six and is dated 30/04/2015. A copy of this
can be found here: http://www.nets.nihr.ac.uk/projects/
hta/1010102 . The FOCUS Trial is sponsored by Greater
Manchester West Mental Health NHS Foundation Trust.
Full contact information for the sponsor can be found
here: https://www.gmw.nhs.uk/research.
Trial oversight
Oversight of the trial is provided by an Independent Data
Monitoring Committee (IDMC). The IDMC is composed
of two clinicians working in the area of psychosis (one of
whom is the IDMC chair), a service user-led researcher
and a statistician, all of whom are independent of the re-
search team and have no competing interests. The IDMC
is the only body involved in the FOCUS Trial, which has
access to the unblinded comparative data in order to con-
sider any ethical or safety reasons why the trial should not
continue. The IDMC has convened annually since the trial
commenced. The outcome of each IDMC meeting is re-
ported to the funder via the minutes of the meeting. A
copy of the IDMC charter is retained by the Trial Manager
in the site file. Additionally, oversight is provided by a
Trial Steering Committee (TSC) which is composed of
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independent members, a representative for the sponsor,
the Chief Investigator (CI) and the Trial Manager. The in-
dependent members include: three clinicians (one of whom
is the Chair of the TSC), a service user and a statistician.
The TSC have convened annually since the trial com-
menced and interim reports regarding recruitment and
compliance to follow-up have been provided via email in
between the annual meetings. It is the role of the TSC to
review the progress of the trial in terms of recruitment,
withdrawals, blind breaks, patient safety (including over
view of all adverse events reported to the CI) and ad-
herence to the protocol. The outcome of each meeting
is reported to the funder via the meeting minutes.
The Chair of the IDMC and TSC, and the funder re-
view and agree all proposed changes to the protocol
prior to research ethics committee review and approval.
The sponsor is responsible for auditing the conduct of
the trial.
Interventions
Cognitive Behavioural Therapy for psychosis (CBTp) is
delivered by appropriately qualified psychological thera-
pists (clinical psychologists, counselling psychologists or
other mental health professionals with specialist training
in CBT). CBTp is delivered on an individual basis over a
period of 9 months and includes up to 30 treatment ses-
sions on an approximately weekly basis over the 9-month
treatment window. CBTp is based on a specific cognitive
model [11], since there is good evidence that CBTp based
on empirically validated models is far superior to more
eclectic cognitive behavioural approaches [29]. CBTp is
based on a manualised approach in which, the assessment
allows the development of an individualised formulation
based on the cognitive model. The specific interventions
are dependent on the individual formulation, but the
range of permissible interventions is described in our
published manuals [12, 30]. The aims of CBTp are to
reduce distress (particularly that associated with psychotic
symptoms) and improve quality of life. It is a collaborative
therapy that works with the problems and goals that are
agreed between patient and therapist. Thus, treatment tar-
gets often include positive symptoms, but frequently also
include social issues such as improving relationships or
developing meaningful social roles and issues of comor-
bidity including anxiety and depression. If comorbidity in-
cludes problematic drug or alcohol use, this can also be
prioritised. Fidelity to the treatment protocol is ensured
by weekly supervision of the therapists and assessed by
rating audio recordings of therapy sessions using the
Cognitive Therapy Scale-Revised [31]. All therapists in
participating centres received initial training, which con-
sisted of a residential week that covered assessment and
formulation based on a specific cognitive model [11],
milestones and assumptions for the therapy process and
change strategies. Therapy supervision is provided by
means of weekly face to face or telephone meetings. All
CBTp sessions are audio recorded with the patient’s
consent (patients may be asked to listen to the tapes as
part of their homework) and a sample of tapes are rated
using the CTSR in order to monitor fidelity and assist
supervision; this is done throughout the lifetime of the
trial in order to provide quality assurance and ensure
corrective action can be taken if required. Following
each session, therapists complete a session record that
monitors the content of the session in terms of agenda
targets, homework tasks and change strategies used.
Thus, fidelity can be used as a mediating variable in
supporting analyses. Additionally, this data is used
throughout the trial to monitor adherence and address
any adherence difficulties with therapist training ses-
sions. The session records are anonymised and stored
electronically in a database that is only accessible to
specific members of staff who have been granted the
necessary privileges. We would consider discontinuing
therapy at the participants request to do so.
The control condition is treatment as usual. We do
not ask clinical teams to withhold any treatment. Our
assessments at baseline, 9 months (end of treatment)
and 21 months (12-month follow-up) identify any risks
to self or others that require immediate action. In
addition, participants in both groups also receive a crisis
card providing emergency contact details. All partici-
pants have an allocated keyworker/care coordinator and
receive follow-up from a multi-disciplinary team within
secondary mental health services. There is a clear safety
protocol to alert clinicians should suicidal or dangerous
ideation emerge. All routine or additional treatments in
both conditions are monitored using the Economic
Patient Questionnaire [32].
Sample size
As we intended to estimate treatment effects across a
range of outcomes, including recovery, in addition to
psychiatric symptoms, we powered the study to detect a
generic effect size of 0.33. With 194 participants per
group, using a t-test with a significance level of 0.05 we
would have 90 % power to detect an effect size of 0.33.
A target recruitment of 485 allowed for a dropout rate
of 20 %.
Referral and recruitment
We recruited participants to the trial through referrals
from community mental health care and inpatient set-
tings across five sites in the UK (Glasgow, Edinburgh,
Manchester, Newcastle and Southampton). In total, this
has included 15 National Health Service (NHS) Trusts
across the UK. Relevant mental health services were
informed about the study through leaflets, attendance
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at team meetings and workshops/talks delivered by the
research team. We also accepted self-referrals through
study leaflets and posters, which were displayed in the
waiting rooms of relevant mental health services. Refer-
rals from both clinicians and service users (self-referrals)
were taken by the research assistants working on the
trial. Basic contact details and information pertaining
to inclusion/exclusion criteria were taken at the point
of referral, for self-referrals we informed the potential
participant that we would need to contact their care
team for referral information and sought verbal consent
to do so. Potential participants were sent a participant
information sheet and given at least 24 h to consider
their involvement. Research assistant met with poten-
tial participants to discuss the participant information
sheet and obtain informed consent. Recruitment was
supported by the Scottish Mental Health Research
Network (SMHRN) and the Mental Health Research
Network (MHRN).
Inclusion criteria
Patients were required to meet the following criteria to
be eligible for enrolment:
1. A criterion level of persistent symptom severity
despite an adequate trial of clozapine in terms of
dosage, duration and adherence [33]:
– Treatment of clozapine at a stable dose of
400 mg or more (unless limited by tolerability)
for at least 12 weeks, or if currently augmented
with a second antipsychotic that this has been
given for at least 12 weeks, without remission
of psychotic symptoms, or have discontinued
clozapine due to adverse reactions (including
agranulocytosis) or lack of efficacy in the past
24 months.
2. Presence of at least one psychotic symptom
with severity ≥4 (for hallucinations/delusions)
or ≥5 (for suspiciousness/grandiosity) on the
Positive and Negative Syndrome Scale (PANSS)
in addition to a PANSS total score of at least 58,
which is equivalent to a clinical global impression
(CGI) of being at least mildly ill [34].
3. Be in contact with mental health services and have
a care coordinator.
4. Either meet ICD-10 criteria for schizophrenia,
schizoaffective disorder or delusional disorder or
meet entry criteria for an Early Intervention for
Psychosis service (operationally defined using
PANSS) in order to allow for diagnostic uncertainty
in early phases of psychosis.
5. Aged at least 16 years’ old
6. Competent and willing to provide written,
informed consent.
Exclusion criteria
1. Primary diagnosis of alcohol/substance dependence,
where this is clearly the cause of their psychotic
symptoms.
2. Developmental disability.
3. Non-English speaking.
4. Current receipt (or within the last 12 months) of
structured CBTp from a qualified psychological
therapist in accordance with NICE guideline
recommendations (as opposed to more generic
psychosocial interventions).
Informed consent
If a person expressed an interest in the trial, they were
provided with a NREC approved Participant Information
Sheet and given at least 24 h to consider their involve-
ment. Those who expressed an interested in participa-
tion were asked to provide written informed consent
prior to their inclusion. Each participant was provided
with a copy of their signed consent form. The consent
form was also copied to the participant’s General Practi-
tioner and allocated mental health professional from
their care team. The research team retain a copy of all
the consent forms.
Data collection and management
All of the information that is collected about participants
is strictly confidential. All personally identifiable informa-
tion, such as participant name, is stored separately to the
research data. All research data is anonymised with a trial
ID number. Participants are made aware that although
their data is strictly confidential and not shared out with
the research team, this confidentiality can be broken if the
participants are deemed a risk to themselves or others.
All personal information is stored securely in paper
format (in locked cabinets in locked University and
NHS Offices) and electronically in a password protected
database, which is only accessible to the research team.
Research data is stored securely in paper format in locked
cabinets in University and NHS Offices and electronically
on a study-specific web-based portal (OpenCDMS; see
above for full details). Data is entered into OpenCDMS by
the research assistants. In order to ensure the accuracy of
the data entered into OpenCDMS the main outcome
measure entries are checked for every participant. This in-
volves checking the scores in the paper file against the
scored entered into the electronic database OpenCDMS.
An error rate of no more than 2 % is acceptable. This is
done once all possible assessments for each time point
have been completed. If the error rate is higher than 2 %
advice will be sought from the trial statistician and metho-
dologist regarding further data checking. The baseline
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period is now complete and the error rate was less than
2 % at all sites.
The final trial dataset will be managed and held by our
Clinical Trials Unit (CTU), The Centre for Healthcare
Randomised Trials (CHaRT) and requests for access to
the dataset will be made in the first instance to the CI
and then the CTU.
Assessment of eligibility and outcome measures
The time schedule of enrolment, interventions and assess-
ments for participants can be seen in Fig. 1. At the point
of referral, basic information pertaining to the inclusion
and exclusion criteria was sought from the clinical team,
this included information relating to clozapine use, diag-
nosis, age, developmental disability, language and current/
previous receipt of CBT. Research assistants (RA) met
with potential participants before the first assessment to
explain the trial, discuss the participant information sheet
and provide an opportunity for the potential participant to
ask questions. After this, the RA sought written informed
consent from those who wish to take part in the trial.
Eligibility on the PANSS was determined at the baseline
assessment.
The primary outcome measure is the total PANSS
score at 21-month assessment (12 months’ follow-up
from the end of treatment). The primary outcome will
allow for comparison with other published trials, inclu-
sion of our results in any future systematic reviews and
meta-analyses. Having the primary outcome at 12-month
follow-up will allow an evaluation of the benefits of CBTp
beyond the end of treatment. The PANSS is a 30-item
rating scale designed to provide a comprehensive as-
sessment of psychopathology in adult patients with schizo-
phrenia. Five components have been reported: positive,
negative, depression-anxiety, agitation-excitement, and
disorganisation [35, 36]. The PANSS was completed at
Eligibility Assessment includes Primary Outcome (PANSS)
Enrolment
Allocation
3-month telephone assessment (health 
economics service receipt only)
Follow-Up
21-months assessment (Primary end-
point)
Includes Primary Outcome (PANSS)
Informed Consent
Randomized 
TAU AloneCBT plus TAU
6-month telephone assessment (health 
economics only)
9-month assessment 
Includes Primary Outcome (PANSS)
13-month telephone assessment (health 
economics only)
17-month telephone assessment (health 
economics only)
3-month telephone assessment (health 
economics service receipt only)
6-month telephone assessment (health 
economics only)
9-month assessment (end of treatment)
Includes Primary Outcome (PANSS)
13-month assessment (health 
economics only)
17-month telephone assessment (health 
economics only)
21-month assessment (Primary end-
point)
Includes Primary Outcome (PANSS)
Fig. 1 Trial flow diagram
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baseline assessment, 9-month follow-up and 21-month
follow-up.
In addition to the PANSS, we administered a number
of other measures at baseline assessment. The Psychotic
Symptom Rating Scales (PSYRATS) [37] was used to as-
sess dimensions of auditory hallucinations and delusional
beliefs including frequency, preoccupation, location, loud-
ness, conviction, and amount of unpleasant content, se-
verity of unpleasant content, amount of distress, intensity
of distress, degree and impairment of control. Personal
and social occupational functioning was assessed by the
Personal and Social Performance Scale (PSP) [38], this
provided an assessment of functioning in four areas
(socially useful activities, personal and social relation-
ships, self-care and aggressive behaviours). Depression
was assessed using the Calgary Depression Rating Scale
for Schizophrenia (CDSS) [39]. Global illness severity
was assessed using the Clinical Global Impression Scale
(CGI) [40] and in addition to the clinician version a
participant version (CGI-P) was utilised to obtain the
participants perception of the severity of their mental
health difficulties. Working memory was assessed using
the Working Memory Letter Number (LN) span [41].
Furthermore, the participants were asked to complete a
number of self-report questionnaires. These include: meta-
worry subscale of the Anxious Thoughts Inventory (ATI
[42]), The Process of Recovery Questionnaire (QPR [43]),
the Alcohol Use Disorder Test (AUDIT [44]) and the Drug
Abuse Screening Test (DAST [45]). Several self-report psy-
chological measures were used to identify mechanisms of
change and predictors of outcome these include the Inter-
pretation of Voices Inventory, (IVI [46]) as a measure of
appraisals of voices; the Beliefs About Paranoia Scale
(BAPS [47]) as a measure of appraisals of paranoia; the
Psychosis Attachment measure (PAM [48]) as a measure
of attachment style; the Brief Core Schema Scale (BCSS
[49]) as an measure of positive and negative beliefs about
others; the Internalised Stigma Scale (ISMI [50]) and the
Common Responses Questionnaire, which is a measure of
common responses to psychotic experiences.
Following the baseline assessment, we invited all
participants to attend two face-to-face assessments at
9 months (end of treatment) and 21 months (12-month
follow-up). All of the measures detailed above are com-
pleted at the 9-month assessment with the addition of the
Childhood Trauma Questionnaire (CTQ [51]), which is
used to retrospectively assess histories of abuse and neg-
lect. All of the measures listed above are also completed at
21-month follow-up with the exception of the Working
Memory Letter Number (LN) and the CTQ. We also ask
all participants at the 21-month follow-up to complete a
self-report measure of potential adverse effects from trial
involvement. This measure was developed specifically for
use in the FOCUS trial to measure these broad categories:
worsening difficulties; poor engagement (including low mo-
tivation); situational change; not getting benefit; stigma; in-
creased conflict with others (care team, family etc.) and
feeling better.
The Economic Patient Questionnaire (EPQ [32]) at
baseline, 3, 6, 9, 13, 17 and 21 months is used to collect
data from participants about the range and frequency of
health and social care services used. The EPQ is used to
identify hospital care and details of this are collected
from case notes. The EPQ is administered by telephone
at the 3, 6, 13 and 17 months’ follow-up. The Euroqol
(EQ-5D) is a generic and validated health status ques-
tionnaire, shown to have acceptable validity in people
with schizophrenia in European countries [52] and used
in previous trials of interventions for people with schizo-
phrenia [32, 53]. It was administered at baseline, 9 and
21 months’ follow-up. Quality adjusted life years (QALYs)
gained from baseline to end of scheduled follow-up will be
estimated as the number of weeks multiplied by the utility
of observed survival. The utility values will be estimated
from the Euroqol EQ-5D health status questionnaire com-
pleted at each follow-up assessment and the associated
published societal utility tariffs.
Participants are offered choice regarding the duration of
the of assessments visit, including the option of breaks
and multiple assessment sessions. Assessment measures
are clearly prioritised so that the most important are col-
lected first to avoid missing data. We have a standard
protocol for managing any distress that is associated with
the completion of measures, which has been developed in
collaboration with service users; this includes the offer of
telephone contact within 48 h of assessments in order to
check on participant well-being.
Participant change of status
If a participant express that they are unsure whether
they wish to remain in therapy, data collection or both,
then they are provided with a range of options (reduced
number of assessment measures, change in time and
venue of their appointments, taking a break from therapy
or delaying assessments) to ensure they have been pro-
vided with a flexible range of choices. If a participant wish
to withdraw from therapy, data collection or both they
can do so at any point without having to provide a reason.
However, participants are offered the option of providing
a reason for withdrawal if they wish to do so. Participants
are also offered the choice to complete the self-report
measure of potential adverse effects from the trial and re-
turn it to the trial manager in a pre-paid envelope.
Safety monitoring and reporting
We record all events which meet National Research Ethics
Committee (NREC) criteria for a serious adverse event
(SAE), i.e. any untoward occurrence that: results in
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death, is life threatening, results in self-harm, results in
harm to others, requires hospitalisation or prolongation
hospitalisation, results in persistent or significant disability
or incapacity, consists of a congenital anomaly or birth de-
fect, or is otherwise considered medically significant by
the investigator. In line with NREC guidance, a SAE oc-
curring to a research participant is reported to the main
REC where in the opinion of the Chief Investigator the
event is related (i.e. resulted from any of the research pro-
cedures) and unexpected. To minimise the risk of bias in
the appraisal of whether the event is related and unex-
pected, we seek an independent opinion for each event
from a representative of the IDMC, who is an expert clini-
cian in the area of psychosis. The IDMC and ITSC provide
oversight of the adverse events and monitor for any pat-
terns in events between the CBT plus TAU and TAU
Alone arms of the trial.
In addition to the above, potential unwanted effects of
trial participation will be reported as a PANSS 25 % or
more deterioration, scores of six or more on the GCI-
Improvement Scale and the adverse effects of trial par-
ticipation self-report measure.
Statistical analysis
Statistical analysis will take place after full recruitment
and follow-up (i.e. there will be no interim analyses for
efficacy, although an independent Data Monitoring
Committee monitors trial progress and specifically any
safety issues on a regular basis). The results of the trial
will be presented following the standard CONSORT
recommendations. Baseline and follow-up data will be
summarised using the appropriate descriptive statistics
and graphical summaries. Treatment effects will be pre-
sented with 95 % confidence intervals (CI). There will
be no adjustment to secondary outcomes CIs for mul-
tiple testing. The primary outcome (PANSS total score
at 21 months) will be analysed using a linear model that
adjusts for pre-specified baseline covariates (baseline
PANSS, sex, age) and includes a random effect for site.
The development of treatment effects over time will be
explored using a repeated measures mixed effects
model that makes use of all available data, this assumes
missing at random conditional on the observed covari-
ates. The primary analysis will be intention-to-treat on
available data (i.e. analyse as randomised). Secondary
outcomes will be analysed in a similar way with genera-
lised linear models appropriate for the distribution of
the outcome.
We will try to identify subgroups for which the treat-
ment effect is greatest using a prognostic risk model
using baseline information. Response to treatment as mea-
sured by change in PANSS from baseline to 21 months
will be explored in a general linear model. Covariates will
include age; sex; baseline secondary outcome measures;
childhood trauma; beliefs about self and others; working
memory performance; and treatment allocated. Outcome
analyses will be repeated excluding participants where the
blind was broken to determine the robustness of the
findings.
We will also address the influence of compliance and
the therapeutic alliance between therapist and partici-
pant via causal or ‘mediation’ models. Traditional ap-
proaches to mediation [54] assume that confounding
between the putative mediator and clinical outcome is
absent (i.e. there is no omitted variable bias). We will
compare the results of three sets of assumptions: (a) no
confounding, (b) that we have measured and are able to
adjust for all important confounders [55], and (c) that we
are able to effectively adjust for unmeasured confounders
(hidden confounding) using instrumental variable-
based methods, specifically analyses based on principal
stratification [56].
The sensitivities of all treatment effect estimates to
missing outcome data will be explored; these models will
explore the robustness of the treatment estimates to
whatever small amount of missing data there is. The fol-
lowing strategy will be followed: firstly, the main analysis
will use all available data that we believe are valid under
the assumption of missing at random; secondly, a suite
of sensitivity analysis to explore the robustness of the
primary analysis to departures from assumptions that in-
cludes all randomised participants; finally, if required,
sensitivity analyses will include multiple imputation, and
imputing a range of values for missing data under missing
not at random assumptions [57].
Data missing at baseline will be reported as such. If re-
quired for models for primary or secondary outcomes,
continuous data will be imputed with the centre specific
mean of that variable, missing binary/categorical data
will include a missing indicator.
A copy of the intention to treat statistical analysis
plan can be found here: http://w3.abdn.ac.uk/hsru/
CHaRT/public/content/ShowPage.aspx?page=statistical-
analysis-plans.
The economic analysis will estimate the costs of
health and social care and quality adjusted life years
(QALYs) from a broad societal perspective. This will
include NHS secondary and primary care services, for-
mal, independent and voluntary social care services and
patients and family expenditure. The key determinants
of total direct costs are expected to be those associated
with the use of NHS hospital inpatient, outpatient and
clinical services provided for the initial trial interven-
tions and associated follow-up. These items comprised
approximately 90 % of the total costs for participants
in the recent CUtLASS trial who were randomised to
second generation antipsychotics [32]. The time hori-
zon for the economic analysis will be the 21 months
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from recruitment to end of scheduled follow-up.
Quality adjusted life years will be the measure of
health benefit from the primary analysis. Changes on
key clinical measures from baseline to follow-up will
be used in sensitivity analyses. QALYs will be mea-
sured using the EQ-5D health status measure and
associated utility tariffs. Missing cost and QALY data
will be treated as described above. Covariates for the
cost effectiveness analyses will be identified from pre-
vious trials and descriptive analysis of the pooled base-
line data.
Dissemination will occur via a number of methods
which include publication of trial papers, conference
presentations, book chapters, the Psychosis Research
Unit website www.psychosisresearch.com and the HTA
final report (monograph and trials directory). All authors
must have contributed to one of each of the following:
the design (conception and design or, acquisition of data
and/or analysis and interpretation of data), the manuscript
(drafting of the manuscript and/or critical revision of the
manuscript for important intellectual content) and prac-
tical issues (statistical expertise, or obtaining funding, or
administrative, technical, or material support, or super-
vision, or no additional contributions or other practical
issues).
Participants will be informed of the results by being
offered written and/or face-to-face feedback. This will be
led by two co-applicants who are user-led researchers
and members of the Psychosis Research Unit (PRU) Service
User Research Group (SURG) have agreed to contribute to
the process of communicating study findings, such as
helping to generate a user-friendly sheet summarising
the findings.
We intend to make data available to the scientific
community with as few restrictions as feasible, while
retaining exclusive use until the publication of major
outputs has been completed.
Discussion
For people diagnosed with schizophrenia who are un-
able to tolerate, or whose symptoms have a limited
response to clozapine there is limited evidence for al-
ternative treatments. There is therefore, an urgent
need to evaluate evidence-based treatment options for
this group of people. To our knowledge, our trial is
the largest definitive trial of CBTp to date. It is the
first multi-site, randomised, controlled trial of its size
to investigate the clinical and cost effectiveness of
CBTp in a strictly-defined, clozapine-resistant schizo-
phrenia group. Recruitment to the trial has ended and
we have recruited successfully to target. Indeed, we
over-recruited to the trial by two participants, achieving
a final total of 487 out of a target of 485.
Our trial has a number of unique features. A strength
of the trial is that we collect the primary outcome data
12-months from the end of the treatment window. This
provides an opportunity to determine the medium-range
effects of CBTp and is unlike many other trials that have a
primary outcome at end of treatment [58]. This is likely to
be of particular importance given the findings from a meta-
analysis of CBTp that the benefits of CBT may be delayed
for up to a few months after treatment has ended [58].
Understanding and quantifying the risk of potential
adverse effects of CBTp is important and early CBTp
trials have been criticised for not giving this issue ad-
equate consideration [59]. Klingberg et al. [60] have
provided a useful template for assessing adverse effects
as defined by the following criteria: (1) death by suicide,
(2) suicide attempt, (3) suicidal crisis (explicit plan for
serious suicidal activity without suicide attempt as de-
fined by item 8, rating of 2 on the Calgary Depression
Rating Scale for Schizophrenia; CDSS) and (4) severe
symptomatic exacerbation (defined by the Clinical
Global Impression Scale; CGI). We measure and re-
port criteria 1–3 as part of National Research Ethics
Committee requirements for recording and reporting
serious adverse events. Additionally, we capture po-
tential unwanted side effects from trial participation
from scores on the CDSS and CGI. We will report
scores of 6 or more on the GCI-Improvement Scale at
9 and 21 months’ follow-up. Furthermore, in order to
capture the participants, own experiences and per-
spectives on trial participation we developed a bespoke
measure of adverse effects from trial participation,
which participants complete at the 21-month follow-
up or are were offered at the point of withdrawal from
the trial. Item generation was via a review of relevant
literature on assessing adverse effects in psychotherapy
trials [60, 61]. In relation to CBTp, we are also exploring
the acceptability of CBTp through a qualitative evalu-
ation of participants’ subjective experiences and percep-
tions of CBTp during the FOCUS trial. This aspect of
the trial is led by service users.
It is unclear from the literature whether the treatment
effects of CBTp may be greater for certain subgroups of
people with a schizophrenia diagnosis. Such information
would prove beneficial for people who have experience
of psychosis and for their clinicians when making in-
formed decisions about accessing CBTp. With this in
mind, we seek to identify subgroups for which the treat-
ment effect is greatest.
In summary, there an urgent need for evidence based
treatments for people with a diagnosis of schizophrenia
who are unable to tolerate or have experienced an inad-
equate response to clozapine. This trial addresses the
question of whether CBTp is an effective treatment option
for this group.
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